Welcome to our dedicated page for Trinity Capital news (Ticker: TRIN), a resource for investors and traders seeking the latest updates and insights on Trinity Capital stock.
Trinity Capital Inc. (TRIN) provides venture lending and equipment financing solutions to growth-stage companies across technology, healthcare, and clean energy sectors. This news hub offers investors and business leaders centralized access to official updates and market insights.
Track all material developments through press releases covering earnings announcements, strategic partnerships, and portfolio company milestones. Our curated collection ensures timely access to information about TRIN's lending activities, risk management practices, and industry leadership in alternative asset management.
Key updates include financing agreements with venture-backed enterprises, portfolio performance metrics, and executive commentary on market trends. Bookmark this page to monitor how TRIN continues to support innovation through structured credit solutions while maintaining disciplined capital preservation strategies.
Trinity Capital Inc. (Nasdaq: TRIN) has reported significant investment activity for Q1 2025, with $220 million in total investments funded. The funding breakdown includes:
- $148 million in secured loans
- $71 million in equipment financings
- $1 million in warrant and equity investments
The company originated $186 million in new commitments, distributing $95 million to six new portfolio companies and $125 million to 19 existing portfolio companies. Portfolio repayments and exits totaled $157 million, comprising $78 million from scheduled debt payments, $44 million from early repayments, and $35 million from sold investments. Complete Q1 2025 financial results will be released on May 7, 2025.
Trinity Capital Inc. (TRIN) has scheduled its first quarter 2025 financial results announcement for May 7, 2025 at 8:00 a.m. ET. The company will host a conference call at 12:00 p.m. ET on the same day to discuss the results.
Investors can access the call by dialing (800) 267-6316 domestically or (203) 518-9783 internationally, using Conference ID: TRINQ125. A taped replay will be available until May 14, 2025, accessible at (800) 839-4197 or (402) 220-2987. Additionally, a live webcast will be available on the company's Investor Relations website, with the replay remaining accessible for 90 days following the call.
Trinity Capital Inc. (NASDAQ: TRIN) has committed up to $68.75 million in growth capital to CMR Surgical, as part of the company's recent $200+ million financing round. CMR Surgical, based in Cambridge, UK, develops the Versius Surgical Robotic System, a soft-tissue surgical robot recently granted FDA marketing authorization for Cholecystectomy procedures in the United States.
The funding will support CMR Surgical's operational scaling and commercial expansion globally, with a particular focus on the U.S. market launch. The company aims to make robotic minimal access surgery more accessible and affordable for hospitals and surgical teams worldwide.
Trinity Capital (Nasdaq: TRIN) has declared a quarterly cash dividend of $0.51 per share for Q1 2025, maintaining the same level as Q4 2024. This marks the company's 21st consecutive quarter of consistent or increased dividend payments to shareholders.
The company aims to distribute quarterly dividends totaling 90% to 100% of its taxable quarterly income to maintain its regulated investment company tax status. Trinity may also pay supplemental dividends to distribute approximately all annual taxable income in the year earned, or carry over excess taxable income for future dividend payments.
Trinity Capital (NASDAQ: TRIN) has appointed Zach Taffet as Director of Capital Formation & Investor Relations to strengthen its institutional fundraising initiatives. Taffet, who previously served on BlackRock's Infrastructure Capital Formation Team, brings nearly a decade of experience in capital raising and investor relations.
During his tenure at BlackRock, Taffet was instrumental in securing $13 billion in institutional capital commitments across multiple funds and played a important role in launching the franchise's fifth vintage fund. In his new role at Trinity, he will help drive the strategic direction for the company's private fund strategies and manage institutional capital through its RIA platform.
Trinity Capital Inc. (NASDAQ: TRIN) has announced the appointment of John Orlando as Managing Director of Life Sciences, based in Boston, expanding its presence to the East Coast. Orlando, who brings over a decade of venture lending experience, joins from Flagship Pioneering where he led debt advisory functions. Prior to this, he provided debt and banking services at J.P. Morgan and Pacific Western Bank.
The appointment strengthens Trinity's Life Sciences division, with Orlando reporting to Rob Lake, Senior Managing Director of Life Sciences. The move signals Trinity's strategic expansion in the Northeast region, leveraging Orlando's industry relationships and expertise in venture lending.
Trinity Capital (TRIN) reported strong Q4 and full-year 2024 results, marking significant growth across key metrics. Q4 highlights include total investment income of $70.8 million (up 48.1% YoY), record net investment income of $34.6 million ($0.58 per share), and a 17.4% Return on Average Equity.
The company achieved total gross investments of $297.3 million in Q4, including $233.4 million in 9 new portfolio companies. Full-year 2024 performance showed total investment income of $237.7 million (30.7% YoY increase) and net investment income of $115.8 million ($2.20 per share). Platform assets under management grew 40.6% to $2.0 billion.
The investment portfolio's fair value reached $1.73 billion, comprising 76.5% first-lien loans. The company maintained strong liquidity with $496.6 million available and expanded its KeyBank Credit Facility to $600 million.
Trinity Capital (NASDAQ: TRIN) has committed $15 million in growth capital to Cagent Vascular, a medical device company specializing in serration technology for vessel dilation in endovascular interventions. This funding complements a $45 million equity financing round led by US Venture Partners in 2024.
Cagent Vascular's flagship product, Serranator®, enhances angioplasty procedures by providing more controlled lumen gain with minimal dissection while reducing vessel recoil. The technology has been utilized in over 20,000 procedures and will use the new funding to scale commercial infrastructure and accelerate clinical adoption.
Trinity Capital (Nasdaq: TRIN) has released preliminary financial estimates for Q4 and full-year 2024. The company expects Q4 2024 net investment income between $0.58 to $0.60 per share, with net asset value per share estimated between $13.32 to $13.37 as of December 31, 2024.
The alternative asset manager reports investment assets at fair value of approximately $1.7 billion. The company's non-accrual investments represented about 0.8% of the total debt investment portfolio at fair value and 2.6% at cost as of year-end 2024.
Trinity Capital (NASDAQ: TRIN) has announced a $25 million growth capital commitment to Wisetack, a pay-over-time platform specializing in home services financing. Wisetack's platform integrates with existing home service business software, enabling services like HVAC, plumbing, and pest control providers to offer flexible payment options to their customers.
The capital will be used to scale Wisetack's operations and fund growth initiatives. Ryan Thompson, Managing Director of Tech Lending at Trinity Capital, highlighted Wisetack's exceptional growth trajectory, customer experience, and strong market position as key factors in the investment decision. Wisetack's founder and CEO, Bobby Tzekin, emphasized that the partnership will help accelerate their growth and innovation in the home services market.